Technical Analysis for ONC - Oncolytics Biotech Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.380 | -1.43% | -0.020 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 200 DMA | Bearish | -1.43% | |
| Gapped Down | Weakness | -1.43% | |
| Oversold Stochastic | Weakness | -1.43% | |
| Crossed Above 200 DMA | Bullish | -6.76% | |
| Stochastic Buy Signal | Bullish | -6.76% | |
| Oversold Stochastic | Weakness | -6.76% | |
| NR7 | Range Contraction | -0.72% | |
| Narrow Range Bar | Range Contraction | -0.72% | |
| Oversold Stochastic | Weakness | -0.72% | |
| Lower Bollinger Band Walk | Weakness | 0.00% |
| Alert | Time |
|---|---|
| Down 1% | about 3 hours ago |
| Down 1 ATR | about 24 hours ago |
| Down 5% | 1 day ago |
| Down 3% | 1 day ago |
| Fell Below 200 DMA | 1 day ago |
Get this analysis on your stocks daily!
- Earnings date: 2024-11-01
Oncolytics Biotech Inc. Description
Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Medicine Clinic Cancer RTT Therapy Oncology Clinical Trial Lung Cancer Blastoma Chemotherapy Non Small Cell Lung Cancer Glioblastoma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.32 |
| 52 Week Low | 1.15 |
| Average Volume | 129,329 |
| 200-Day Moving Average | 1.446 |
| 50-Day Moving Average | 1.497 |
| 20-Day Moving Average | 1.550 |
| 10-Day Moving Average | 1.455 |
| Average True Range | 0.096 |
| RSI (14) | 41.18 |
| ADX | 18.18 |
| +DI | 19.285 |
| -DI | 18.575 |
| Chandelier Exit (Long, 3 ATRs) | 1.473 |
| Chandelier Exit (Short, 3 ATRs) | 1.657 |
| Upper Bollinger Bands | 1.768 |
| Lower Bollinger Band | 1.332 |
| Percent B (%b) | 0.16 |
| BandWidth | 28.090 |
| MACD Line | -0.043 |
| MACD Signal Line | -0.019 |
| MACD Histogram | -0.0243 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.505 | ||||
| Resistance 3 (R3) | 1.510 | 1.480 | 1.488 | ||
| Resistance 2 (R2) | 1.480 | 1.453 | 1.478 | 1.482 | |
| Resistance 1 (R1) | 1.440 | 1.437 | 1.425 | 1.435 | 1.476 |
| Pivot Point | 1.410 | 1.410 | 1.403 | 1.408 | 1.410 |
| Support 1 (S1) | 1.370 | 1.383 | 1.355 | 1.365 | 1.324 |
| Support 2 (S2) | 1.340 | 1.367 | 1.338 | 1.318 | |
| Support 3 (S3) | 1.300 | 1.340 | 1.313 | ||
| Support 4 (S4) | 1.295 |
